Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Jul;4(4):415–422. doi: 10.1128/cdli.4.4.415-422.1997

Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

S Romero-Steiner 1, D Libutti 1, L B Pais 1, J Dykes 1, P Anderson 1, J C Whitin 1, H L Keyserling 1, G M Carlone 1
PMCID: PMC170543  PMID: 9220157

Abstract

Host protection against pneumococcal disease i primarily mediated by phagocytosis. We developed and standardized an opsonophagocytic assay using HL-60 cells (human promyelocytic leukemia cells). Fifty-five serum samples were analyzed for the presence of functional antibody against seven pneumococcal serogroups or serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) by using differentiated HL-60 cells (granulocytes) and peripheral blood leukocytes (PBLs). Six of the 55 serum samples were from unvaccinated adult volunteers, 31 serum samples were from adults who received one dose of the 14-valent or the 23-valent polysaccharide vaccine, and 18 serum samples were from 16-month-old infants who received four doses of an investigational 7-valent polysaccharide-protein conjugate vaccine. The results of an opsonophagocytic assay with HL-60 cells correlated highly with those of an assay with PBLs as effector cells (median r for seven serotypes = 0.87: P < 0.01). Opsonophagocytic titers were compared with the immunoglobulin G antibody concentrations determined by enzyme-linked immunosorbent assay (ELISA). The r values for serogroups or serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were 0.61, 0.60, 0.67 0.90, 0.61, 0.39, and 0.57, respectively, when HL-60 cells were used as effector cells and 0.56, 0.47, 0.61, 0.90, 0.71, 0.31, and 0.62, respectively, when PBLs were used. The assay requires small amounts of serum (40 microliters per serotype), making this test suitable for assaying infant sera. Culturable cells aid in assay standardization and likely reduce donor-to-donor variability. This standardized assay, in combination with the standardized ELISA, can be used to evaluate current and developing pneumococcal vaccines, in which functional opsonophagocytic antibody activity may correlate with protection against pneumococcal disease.

Full Text

The Full Text of this article is available as a PDF (178.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alonso de Velasco E., Verheul A. F., van Steijn A. M., Dekker H. A., Feldman R. G., Fernández I. M., Kamerling J. P., Vliegenthart J. F., Verhoef J., Snippe H. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect Immun. 1994 Mar;62(3):799–808. doi: 10.1128/iai.62.3.799-808.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. AlonsoDeVelasco E., Verheul A. F., Verhoef J., Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev. 1995 Dec;59(4):591–603. doi: 10.1128/mr.59.4.591-603.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkinson J. P., Jones E. A. Biosynthesis of the human C3b/C4b receptor during differentiation of the HL-60 cell line. Identification and characterization of a precursor molecule. J Clin Invest. 1984 Nov;74(5):1649–1657. doi: 10.1172/JCI111581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boyd A. W., Metcalf D. Induction of differentiation in HL60 leukaemic cells: a cell cycle dependent all-or-none event. Leuk Res. 1984;8(1):27–43. doi: 10.1016/0145-2126(84)90029-8. [DOI] [PubMed] [Google Scholar]
  5. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  6. Bruyn G. A., Zegers B. J., van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis. 1992 Jan;14(1):251–262. doi: 10.1093/clinids/14.1.251. [DOI] [PubMed] [Google Scholar]
  7. Butler J. C., Breiman R. F., Campbell J. F., Lipman H. B., Broome C. V., Facklam R. R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993 Oct 20;270(15):1826–1831. [PubMed] [Google Scholar]
  8. Collins S. J., Gallo R. C., Gallagher R. E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977 Nov 24;270(5635):347–349. doi: 10.1038/270347a0. [DOI] [PubMed] [Google Scholar]
  9. Collins S. J., Ruscetti F. W., Gallagher R. E., Gallo R. C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A. 1978 May;75(5):2458–2462. doi: 10.1073/pnas.75.5.2458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Collins S. J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 1987 Nov;70(5):1233–1244. [PubMed] [Google Scholar]
  11. Esposito A. L., Clark C. A., Poirier W. J. An assessment of the factors contributing to the killing of type 3 Streptococcus pneumoniae by human polymorphonuclear leukocytes in vitro. APMIS. 1990 Feb;98(2):111–121. [PubMed] [Google Scholar]
  12. Gray B. M. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate). Pediatrics. 1990 Apr;85(4 Pt 2):694–697. [PubMed] [Google Scholar]
  13. Guckian J. C., Christensen G. D., Fine D. P. The role of opsonins in recovery from experimental pneumococcal pneumonia. J Infect Dis. 1980 Aug;142(2):175–190. doi: 10.1093/infdis/142.2.175. [DOI] [PubMed] [Google Scholar]
  14. Guyre P. M., Morganelli P. M., Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest. 1983 Jul;72(1):393–397. doi: 10.1172/JCI110980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Joiner K. A., Brown E. J., Frank M. M. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol. 1984;2:461–491. doi: 10.1146/annurev.iy.02.040184.002333. [DOI] [PubMed] [Google Scholar]
  16. Kaniuk A. S., Lortan J. E., Monteil M. A. Specific IgG subclass antibody levels and phagocytosis of serotype 14 pneumococcus following immunization. Scand J Immunol Suppl. 1992;11:96–98. doi: 10.1111/j.1365-3083.1992.tb01628.x. [DOI] [PubMed] [Google Scholar]
  17. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J. 1987 Jun;6(6):519–526. doi: 10.1097/00006454-198706000-00006. [DOI] [PubMed] [Google Scholar]
  18. Lee C. J., Lock R. A., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate. Vaccine. 1994 Aug;12(10):875–878. doi: 10.1016/0264-410x(94)90028-0. [DOI] [PubMed] [Google Scholar]
  19. Lortan J. E., Kaniuk A. S., Monteil M. A. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol. 1993 Jan;91(1):54–57. doi: 10.1111/j.1365-2249.1993.tb03353.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Musher D. M., Watson D. A., Baughn R. E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis. 1990 Apr;161(4):736–740. doi: 10.1093/infdis/161.4.736. [DOI] [PubMed] [Google Scholar]
  21. Nahm M. H., Siber G. R., Olander J. V. A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. J Infect Dis. 1996 Jan;173(1):113–118. doi: 10.1093/infdis/173.1.113. [DOI] [PubMed] [Google Scholar]
  22. Nielsen S. V., Sørensen U. B., Henrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog. 1993 Apr;14(4):299–305. doi: 10.1006/mpat.1993.1029. [DOI] [PubMed] [Google Scholar]
  23. Obaro S. K., Henderson D. C., Monteil M. A. Defective antibody-mediated opsonisation of S. pneumoniae in high risk patients detected by flow cytometry. Immunol Lett. 1996 Jan;49(1-2):83–89. doi: 10.1016/0165-2478(95)02487-5. [DOI] [PubMed] [Google Scholar]
  24. Osborne J. M., Chacko G. W., Brandt J. T., Anderson C. L. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. J Immunol Methods. 1994 Aug 1;173(2):207–217. doi: 10.1016/0022-1759(94)90299-2. [DOI] [PubMed] [Google Scholar]
  25. Plikaytis B. D., Holder P. F., Pais L. B., Maslanka S. E., Gheesling L. L., Carlone G. M. Determination of parallelism and nonparallelism in bioassay dilution curves. J Clin Microbiol. 1994 Oct;32(10):2441–2447. doi: 10.1128/jcm.32.10.2441-2447.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Quataert S. A., Kirch C. S., Wiedl L. J., Phipps D. C., Strohmeyer S., Cimino C. O., Skuse J., Madore D. V. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995 Sep;2(5):590–597. doi: 10.1128/cdli.2.5.590-597.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sanders L. A., van de Winkel J. G., Rijkers G. T., Voorhorst-Ogink M. M., de Haas M., Capel P. J., Zegers B. J. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis. 1994 Oct;170(4):854–861. doi: 10.1093/infdis/170.4.854. [DOI] [PubMed] [Google Scholar]
  28. Schiffman G., Douglas R. M., Bonner M. J., Robbins M., Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods. 1980;33(2):133–144. doi: 10.1016/s0022-1759(80)80004-4. [DOI] [PubMed] [Google Scholar]
  29. Shapiro E. D., Austrian R. Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut. J Infect Dis. 1994 Jan;169(1):212–214. doi: 10.1093/infdis/169.1.212. [DOI] [PubMed] [Google Scholar]
  30. Siber G. R. Pneumococcal disease: prospects for a new generation of vaccines. Science. 1994 Sep 2;265(5177):1385–1387. doi: 10.1126/science.8073278. [DOI] [PubMed] [Google Scholar]
  31. Stansfield S. K. Acute respiratory infections in the developing world: strategies for prevention, treatment and control. Pediatr Infect Dis J. 1987 Jul;6(7):622–629. doi: 10.1097/00006454-198707000-00002. [DOI] [PubMed] [Google Scholar]
  32. Sveum R. J., Chused T. M., Frank M. M., Brown E. J. A quantitative fluorescent method for measurement of bacterial adherence and phagocytosis. J Immunol Methods. 1986 Jun 24;90(2):257–264. doi: 10.1016/0022-1759(86)90083-9. [DOI] [PubMed] [Google Scholar]
  33. Vitharsson G., Jónsdóttir I., Jónsson S., Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis. 1994 Sep;170(3):592–599. doi: 10.1093/infdis/170.3.592. [DOI] [PubMed] [Google Scholar]
  34. Welby P. L., Keller D. S., Cromien J. L., Tebas P., Storch G. A. Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J. 1994 Apr;13(4):281–287. doi: 10.1097/00006454-199404000-00007. [DOI] [PubMed] [Google Scholar]
  35. Wenger J. D., Hightower A. W., Facklam R. R., Gaventa S., Broome C. V. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis. 1990 Dec;162(6):1316–1323. doi: 10.1093/infdis/162.6.1316. [DOI] [PubMed] [Google Scholar]
  36. Winkelstein J. A., Smith M. R., Shin H. S. The role of C3 as an opsonin in the early stages of infection. Proc Soc Exp Biol Med. 1975 Jun;149(2):397–401. doi: 10.3181/00379727-149-38815. [DOI] [PubMed] [Google Scholar]
  37. Winkelstein J. A. The role of complement in the host's defense against Streptococcus pneumoniae. Rev Infect Dis. 1981 Mar-Apr;3(2):289–298. doi: 10.1093/clinids/3.2.289. [DOI] [PubMed] [Google Scholar]
  38. van de Winkel J. G., Anderson C. L. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol. 1991 May;49(5):511–524. doi: 10.1002/jlb.49.5.511. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES